Atherosclerosis, calcium, and calcium antagonists.
D000818:Animals; D001011:Aorta / Q000187:drug effects; D001158:Arteries / Q000187:drug effects; D001161:Arteriosclerosis / Q000209:etiology*; D002114:Calcinosis / Q000150:complications*; D002118:Calcium / Q000037:antagonists & inhibitors*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002470:Cell Survival; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D002936:Cinnarizine / Q000031:analogs & derivatives / Q000494:pharmacology; D004110:Diltiazem / Q000494:pharmacology; D005444:Flunarizine; D006801:Humans; D008563:Membrane Lipids / Q000502:physiology; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009529:Nicardipine; D009543:Nifedipine / Q000031:analogs & derivatives / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011817:Rabbits; D014700:Verapamil / Q000494:pharmacology
D002121:Calcium Channel Blockers; D002791:Cholesterol, Dietary; D008563:Membrane Lipids; D002936:Cinnarizine; D011433:Propranolol; D014700:Verapamil; D009529:Nicardipine; D004110:Diltiazem; D009543:Nifedipine; D005444:Flunarizine; D002118:Calcium